Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ADR Biomedical HoldingsTSE:3750 -0.65%24 Median PS Value is 円36.48 as of Aug. 24, 2026, which is 100% below its 10-year median of 8.98. GuruFocus rates TSE:3750 with a GF Score™ of 24/100 and a GF Value™ of 円39.23 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 282 Biotechnology companies, ADR Biomedical Holdings ranks worse than 98.94% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for ADR Biomedical Holdings's Median PS Value or its related term are showing as below:
TSE:3750'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 1.68 Med: 8.98 Max: 22.31
Current: 20.94
During the past 13 years, the highest Price to Median PS Value of ADR Biomedical Holdings was 22.31. The lowest was 1.68. And the median was 8.98.
TSE:3750's Price-to-Median-PS-Value is ranked worse than 98.94% of 282
companies
in the Biotechnology industry
Industry Median: 0.62
vs TSE:3750: 20.94
ADR Biomedical Holdings (TSE:3750) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
ADR Biomedical Holdings's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
764.00
/
36.48
=
20.94
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADR Biomedical Holdings Median PS Value Related Terms
ADR Biomedical Holdings Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:3750 vs VRTX, REGN, RVMD: Median PS Value Comparison
For the Biotechnology subindustry, ADR Biomedical Holdings's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADR Biomedical Holdings Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADR Biomedical Holdings's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where ADR Biomedical Holdings's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 6.3866.
ADR Biomedical Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円5.712.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADR Biomedical Holdings (TSE:3750) has a Median PS Value of 円36.48 as of Aug. 24, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on ADR Biomedical Holdings and its competitors. This is 306% above median its historical median of 8.98. Over the past decade, ADR Biomedical Holdings' Median PS Value has ranged from 1.68 to 22.31. According to the industry distribution chart, ADR Biomedical Holdings ranks #279 out of 282 companies in the Biotechnology industry, placing it in the top 98.9%.
Is ADR Biomedical Holdings' Median PS Value too high?
ADR Biomedical Holdings' current Median PS Value of 円36.48 is 306% above median its 10-year median of 8.98. Over the past 10 years, this metric has ranged from a low of 1.68 to a high of 22.31. Based on the distribution chart, ADR Biomedical Holdings ranks #279 out of 282 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ADR Biomedical Holdings has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ADR Biomedical Holdings' Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ADR Biomedical Holdings ranks #279 out of 282 companies for Median PS Value. This places ADR Biomedical Holdings in the lower half of its industry. The industry median Median PS Value is 0.62. Historically, ADR Biomedical Holdings' own Median PS Value has ranged from 1.68 to 22.31 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.62, based on 282 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on ADR Biomedical Holdings and its competitors. For the Biotechnology industry, the median Median PS Value is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADR Biomedical Holdings's current Median PS Value is 円36.48, which is 306% above median its own 10-year median of 8.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADR Biomedical Holdings stock overvalued right now?
Based on GuruFocus' analysis, ADR Biomedical Holdings (TSE:3750) is currently considered Significantly Overvalued. The stock's GF Value™ is 円39.23, compared to a current price of 円764.00 — trading 1847.5% above its estimated fair value. The current Median PS Value is 円36.48, which is 306% above median its 10-year median of 8.98. ADR Biomedical Holdings' overall GF Score™ is 24/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For ADR Biomedical Holdings (TSE:3750), the current Median PS Value is 円36.48 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADR Biomedical Holdings (TSE:3750) Overvalued in 2026?
Based on GuruFocus' analysis, ADR Biomedical Holdings stock appears to be overvalued.
The current stock price of 円764.00 is trading 1847.5% above its estimated GF Value™ of 円39.23.
GuruFocus considers ADR Biomedical Holdings to be Significantly Overvalued.
Key valuation signals for TSE:3750:
Median PS Value: 円36.48 (306% above median its 10-year median of 8.98)
GF Value™: 円39.23 vs. price of 円764.00 (1847.5% above fair value)
No single metric tells the full story. See the TSE:3750 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADR120S Inc developing a new clinical approach to cell therapy to provide medical care to patients by providing medical care that responds to unmet medical needs based on its regenerative medicine. Its product pipeline includes Habeo; ECCO-50 and others.
24GF Score
Get the complete analysis for TSE:3750
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3750 has been successfully added to your 
